Truist upgrades OrthoPediatrics stock to Hold with USD 26.44 consensus

Published on 10/17/2026 at 21:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 27, 2026. OrthoPediatrics stock costs USD 21.95 on October 16, 2026, down 2.75 percent versus the Nasdaq prior close.

Rating and trading update

Truist Financial moved OrthoPediatrics to a Hold rating on October 1, 2026, while the consensus target was USD 26.44.
OrthoPediatrics is scheduled to report third-quarter results on October 27, 2026.
OrthoPediatrics stock costs USD 21.95 at Nasdaq on October 16, 2026, down 2.75 percent versus the prior close of USD 22.57.
The company had a market capitalization of USD 573.1 million as of October 17, 2026.

KIDS, US68752L1008, Illustration mit AI erstellt.

Truist Financial upgraded OrthoPediatrics to a Hold rating on October 1, 2026, while the broader consensus target stood at USD 26.44, or 20.46 percent above the Nasdaq price of USD 21.95, according to MarketBeat. OrthoPediatrics stock was down 2.75 percent on Nasdaq on October 16, 2026, closing at USD 21.95 versus a prior close of USD 22.57.

Analyst target stays above the price

The USD 26.44 consensus target implies 20.46 percent upside from the USD 21.95 Nasdaq close. MarketBeat reported seven research firms in its October 15, 2026 overview, with five Buy ratings, one Hold and one Sell. The average target in that overview was USD 26.50, while the October 2 report cited USD 26.44, so the exact consensus depends on the publication date.

Recent named views remain mixed. Truist Financial moved its rating to Hold on October 1, 2026, while BTIG Research reiterated Buy with a USD 29.00 target on September 14, 2026, according to MarketBeat. The stock therefore sits below the cited targets, but the rating mix does not point in one direction.

Second-quarter growth sets the base

In the second quarter of 2026, revenue reached USD 70.5 million, up 15 percent from the second quarter of 2025, while adjusted EBITDA increased to USD 6.8 million from USD 4.1 million. The company also raised full-year 2026 revenue guidance to USD 265 million to USD 269 million from USD 263 million to USD 267 million, according to The Globe and Mail. The same call reported a gross profit margin of 74 percent, compared with 72 percent in the prior-year quarter.

Price position and reporting date

OrthoPediatrics traded between USD 14.42 and USD 26.74 over the past 52 weeks. The October 16 close was 17.91 percent below the high and 52.22 percent above the low. Market capitalization stood at USD 573.1 million, and the average volume was 212,593 shares against 149,673 shares in the session.

The company is scheduled to report third-quarter 2026 results on October 27, 2026, at 4:30 p.m. ET, according to OrthoPediatrics. The event is the next dated checkpoint after the second-quarter results and the October analyst updates.

Comparison with peers

KIDS (Nasdaq, USD): minus 2.75 percent, P/E minus 13.07, market capitalization USD 573.1 million

Globus Medical (NYSE, USD): minus 2.70 percent, P/E 19.72, market capitalization USD 10.3 billion

Zimmer Biomet (NYSE, USD): plus 0.64 percent, P/E 23.11, market capitalization USD 18.1 billion

Trading remains below the target range

OrthoPediatrics is valued below the recent consensus targets, while its 52-week position places the stock closer to the midpoint than to either extreme. The upcoming October 27 results will provide the next reported comparison for revenue, margins and guidance.

OrthoPediatrics stock was last at USD 21.95 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 2.75 percent versus the prior close of USD 22.57.